Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma

International Immunopharmacology

Volumn 7, Issue 13, 2007, Pages 1793-1801

  Kim, Hwan Mook ^a   Lim, Jaeseung ^b   Yoon, Yeo Dae ^a   Ahn, Ji Mi ^a   Kang, Jong Soon ^a   Lee, Kiho ^a   Park, Song Kyu ^a   Jeong, Yu Jin ^b   Kim, Jin Mi ^b   Han, Gyoonhee ^c   Yang, Kyu Hwan ^d   Kim, Yeon Jin ^e   Kim, Youngsoo ^e   Han, Sang Bae ^a,e  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Innocell Ltd   (South Korea)

^c Yonsei University   (South Korea)

^d Gachon University College of Medicine   (South Korea)

^e Chungbuk National University   (South Korea)

Author keywords

Adoptive immunotherapy; Cytokine induced killer cells; Hepatocellular carcinoma

Indexed keywords

CD3 ANTIBODY; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CHROMIUM; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL DESTRUCTION;

ANIMALS; ANTIGENS, CD3; ANTIGENS, CD56; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS; LIVER NEOPLASMS, EXPERIMENTAL; MICE;

EID: 35848932103     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.08.007     Document Type: Article

References (36)

1. Kalinski P., Nakamura Y., Watchmaker P., Giermasz A., Muthuswamy R., and Mailliard R.B. Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol Res 36 (2006) 137-146
2. Takashima K., Fujiwara H., Inada S., Atsuji K., Araki Y., Kubota T., et al. Tracking of green fluorescent protein (GFP)-labeled LAK cells in mice carrying B16 melanoma metastases. Anticancer Res 26 (2006) 3327-3332
3. Raja Gabaglia C., Diaz de Durana Y., Graham F.L., Gauldie J., Sercarz E.E., and Braciak T.A. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors. Cancer Res 67 (2007) 2290-2297
4. Wang W., Epler J., Salazar L.G., and Riddell S.R. Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. Cancer Res 66 (2006) 6826-6833
5. Thorne S.H., Negrin R.S., and Contag C.H. Synergistic antitumor effects of immune cell-viral biotherapy. Science 311 (2006) 1780-1784
6. Baker J., Verneris M.R., Ito M., Shizuru J.A., and Negrin R.S. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 97 (2001) 2923-2931
7. Lu P.H., and Negrin R.S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153 (1994) 1687-1696
8. Leemhuis T., Wells S., Scheffold C., Edinger M., and Negrin R.S. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11 (2005) 181-187
9. Verneris M.R., Arshi A., Edinger M., Kornacker M., Natkunam Y., Karami M., et al. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res 11 (2005) 4561-4570
10. Edinger M., Cao Y.A., Verneris M.R., Bachmann M.H., Contag C.H., and Negrin R.S. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 101 (2003) 640-648
11. Thorne S.H., Hermiston T., and Kirn D. Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin Oncol 32 (2005) 537-548
12. Thorne S.H., and Kirn D.H. Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus. Expert Opin Biol Ther 4 (2004) 1307-1321
13. Zhang Y.S., Yuan F.J., Jia G.F., Zhang J.F., Hu L.Y., Huang L., et al. CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol 11 (2005) 3339-3345
14. Wang F.S., Liu M.X., Zhang B., Shi M., Lei Z.Y., Sun W.B., et al. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 8 (2002) 464-468
15. Kim J.H., Han K.H., Lee K.S., Park Y.N., Ahn S.H., Chon C.Y., et al. Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea. Yonsei Med J 47 (2006) 793-798
16. Gonzalez-Carmona M.A., Marten A., Hoffmann P., Schneider C., Sievers E., Schmidt-Wolf I.G., et al. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int 26 (2006) 369-379
17. Shi M., Zhang B., Tang Z.R., Lei Z.Y., Wang H.F., Feng Y.Y., et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 10 (2004) 1146-1151
18. Takayama T., Sekine T., Makuuchi M., Yamasaki S., Kosuge T., Yamamoto J., et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatoellular carcinoma: a randomised trial. Lancet 356 (2000) 802-807
19. Shin E.C., Ahn J.M., Kim C.H., Choi Y., Ahn Y.S., Kim H., et al. IFN-gamma induces cell death in human hepatoma cells through a TRAIL/death receptor-mediated apoptotic pathway. Int J Cancer 93 (2001) 262-268
20. Suh S.I., Pyun H.Y., Cho J.W., Baek W.K., Park J.B., Kwon T., et al. 5-Aza-2′-deoxycytidine leads to down-regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines. Cancer Lett 160 (2000) 81-88
21. Han S.B., Moratz C., Huang N.N., Kelsall B., Cho H., Shi C.S., et al. Rgs1 and Gnai2 regulate the entrance of B lymphocytes into lymph nodes and B cell motility within lymph node follicles. Immunity 22 (2005) 343-354
22. Han S.B., Lee C.W., Yoon Y.D., Kang J.S., Lee K.H., Yoon W.K., et al. Effective prevention of lethal acute graft-versus-host disease by combined immunosuppressive therapy with prodigiosin and cyclosporine A. Biochem Pharmacol 70 (2005) 1518-1526
23. Kanda N., and Watanabe S. Gangliosides GD1b, GT1b, and GQ1b enhance IL-2 and IFN-gamma production and suppress IL-4 and IL-5 production in phytohemagglutinin-stimulated human T cells. J Immunol 166 (2001) 72-80
24. Han S.B., Lee C.W., Jeon Y.J., Hong N.D., Yoo I.D., Yang K.H., et al. The inhibitory effect of polysaccharides isolated from Phellinus linteus on tumor growth and metastasis. Immunopharmacology 41 (1999) 157-164
25. Kim J.Y., Yoon Y.D., Ahn J.M., Kang J.S., Park S.K., Lee K., et al. Angelan isolated from Angelica gigas Nakai induces dendritic cell maturation through toll-like receptor 4. Int Immunopharmacol 7 (2007) 78-87
26. Marten A., Renoth S., von Lilienfeld-Toal M., Buttgereit P., Schakowski F., Glasmacher A., et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 86 (2001) 1029-1037
27. Kornacker M., Verneris M., Kornacker B., Ganten T., Scheffold C., and Negrin R. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab. Cytotherapy 8 (2006) 13-23
28. Chan J.K., Hamilton C.A., Cheung M.K., Karimi M., Baker J., Gall J.M., et al. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 12 (2006) 1859-1867
29. Alvarnas J.C., Linn Y.C., Hope E.G., and Negrin R.S. Expansion of cytotoxic CD3+CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 7 (2001) 216-222
30. Verneris M.R., Kornacker M., Mailander V., and Negrin R.S. Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis. Cancer Immunol Immunother 49 (2000) 335-345
31. Hoyle C., Bangs C.D., Chang P., Kamel O., Mehta B., and Negrin R.S. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 92 (1998) 3318-3327
32. Margolin K.A., Negrin R.S., Wong K.K., Chatterjee S., Wright C., and Forman S.J. Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev 157 (1997) 231-240
33. Schmidt-Wolf I.G., Lefterova P., Mehta B.A., Fernandez L.P., Huhn D., Blume K.G., et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21 (1993) 1673-1679
34. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., Blume K.G., and Weissman I.L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174 (1991) 139-149
35. Kornacker M., Moldenhauer G., Herbst M., Weilguni E., Tita-Nwa F., Harter C., et al. Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma. Int J Cancer 119 (2006) 1377-1382
36. Grabert R.C., Cousens L.P., Smith J.A., Olson S., Gall J., Young W.B., et al. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res 12 (2006) 569-576